The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...
The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...
According to the Centers for Disease Control and Prevention ( CDC ), ovarian cancer may cause vaginal bleeding, pelvic pain, ...
GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...
Zacks.com on MSN9d
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial CancerGSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...
Among patients of child-bearing age, the crucial topic of whether cervical cancer impacts fertility frequently comes up ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
"EC approves GSK’s Jemperli-chemo combo for endometrial cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback